GlassScriptPhysician profile
Mahta Ostadian
NPI 1003044595
$1,510.96
in general payments reported to CMS, 2019-2025
21 companies · $58.58 in 2025
The $58.58 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $174 · 2021: $348 · 2022: $299 · 2023: $101 · 2024: $184 · 2025: $58.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $468.70 | 2019-2025 | Trintellix |
| Abbvie INC. | $235.78 | 2021-2024 | |
| Bausch Health US, LLC | $103.36 | 2021-2022 | |
| Lundbeck LLC | $102.93 | 2019-2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $73.17 | 2019-2022 | |
| Allergan, INC. | $70.97 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $70.27 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.38 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $48.76 | 2019 | |
| Ironshore Pharmaceuticals INC. | $45.26 | 2019-2022 | |
| Medtronic, INC. | $42.87 | 2022-2024 | Vanta Adaptivestim |
| Supernus Pharmaceuticals, INC. | $31.18 | 2024-2025 | Qelbree |
| Shire North American Group INC | $24.06 | 2019 | |
| Neuronetics, INC. | $22.02 | 2020-2024 | Neurostar Tms Therapy System |
| Axsome Therapeutics, INC. | $21.47 | 2024 | Sunosi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $18.48 | 2021 | |
| Neurocrine Biosciences, INC. | $18.40 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.55 | 2019 | |
| Tris Pharma INC | $14.43 | 2023 | Dyanavel Xr |
| Eisai INC. | $14.16 | 2020 | |
| Merck Sharp & Dohme LLC | $13.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahta Ostadian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.